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Background: Heart failure (HF) is associated with decreased quality of life, high re-admission rate and poor
prognosis. In particular, ischemic heart failure (IHF) has a worse prognosis than nonischemic HF. The use of
traditional Chinese medicine (TCM) alongside Western medicine to treat HF has developed into an integrative
treatment model in China. There have been small clinical trials and experimental studies to demonstrate the
efficacy of TCM for treating HF; however, there is still a lack of high-quality trials. Qishen Yiqi dripping pills (QSYQ), a
TCM drug, have been commonly used alongside standardized Western medicine to treat IHF. This paper describes
the protocol for the clinical assessment of QSYQ in IHF patients.
Method: A randomized, double-blind, multicenter, placebo-controlled trial will assess the efficacy and safety of
QSYQ in the treatment of IHF. The trial is to enroll 640 IHF patients from 32 hospitals in China. Besides their
standardized Western medicine, patients will be randomized to receive treatment of either QSYQ or placebo for 6
months and follow-up monitoring for at least a further 6 months. The primary outcome is increased exercise
capacity of patients, which will be measured using the 6-minute walking test (6MWT). The secondary outcomes
include composite endpoints: all-cause mortality, frequency of hospitalization or emergency due to cardiovascular
events, brain natriuretic peptide levels, left ventricular ejection fraction, and cardiothoracic ratio will be
documented, as well as scores on the New York Heart Association classification and Minnesota quality of life index,
and information obtained from the four TCM diagnostic methods. Blood lipid tests will also be administered.
Discussion: The integrative treatment model of TCM alongside Western medicine has developed into a treatment
model in China. The rigorous design of the trial will assure an objective and scientific assessment of the efficacy
and safety of QSYQ in the treatment of IHF.
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Heart failure (HF), as the endstage of various cardiac
diseases, is associated with decreased quality of life, high
re-admission rate, and poor prognosis. Some investiga-
tions showed that ischemic heart disease (IHD) was re-
sponsible for 70% of HF patients, while 40% of IHD
patients died from HF [1-3]. Even with standardized
treatment, the prognosis of patients with ischemic heart
failure (IHF) is worse than in patients with nonischemic
HF, especially for those with severe symptoms (New
York Heart Association (NYHA) class IV) [4]. Their 1-
year and 3-year mortality rates are 18% and 43%, re-
spectively [4]. Nowadays, Western medicine treatment
for HF is standardized around the world [5,6]; however,
the integrative treatment of Western and traditional
Chinese medicine (TCM) for HF is commonly used and
developed as a treatment model in China [6].
Qishen Yiqi dripping pills (QSYQ, produced by Tasly
Pharmaceutical Co. Ltd.), a patent drug made of active
ingredients from Huangqi, Danshen, Sanqi, and
Jiangxiang, has the effect of nourishing Qi, promoting
blood circulation and relieving pain. The pills have been
commonly used in TCM for the integrative treatment of
patients with IHF who are also diagnosed with Qi defi-
ciency and blood stasis syndrome [7,8]. Experimental re-
searches have shown in animal models that QSYQ could
inhibit platelet aggregation, prevent enlargement of end-
diastolic diameter, improve left ventricular function, and
slow down ventricular remodeling [9-14]. Some small-
scale clinical studies on the drug demonstrated efficacies
in improving left ventricular function, increasing exer-
cise capacity and decreasing re-admission rate [15-19].
We would like to test the hypothesis that patients with
IHF will benefit from TCM treatment QSYQ and evalu-
ate its safety through a high-quality clinical trial.
Objective
The objective of the trial is to assess the safety and clin-
ical effects of QSYQ in improving the exercise capacity
of IHF patients.
Design
The CACT-IHF study is designed as a multicenter, ran-
domized, double-blind, placebo-controlled trial, and will
be conducted in 32 level-A hospitals in China. A total of
640 stable outpatients with IHF, who fulfill the inclusion
and exclusion criteria, will be randomized into either a
treatment group or a control group.
Sample size
The sample size calculation was based on results from
studies by Hutcheon et al. [20] and Mao et al. [21]. After
6 months of intervention, we assume that the distance
walked in a 6-minute walking test (6MWT ) in the controlgroup and treatment group will be up to 260 m and 288
m, respectively (that is, patients in the treatment group
will walk an additional 28 m, δ = 115 m). Patients will be
randomized in the ratio of 1:1 into two groups and each
group requires at least 266 patients in order to produce
positive results (one-tailed test, significant level α = 0.05,
power (1 − β) = 0.80). Considering the loss of patients due
to follow-up and a maximum dropout rate of less than or
equal to 20%, the sample size was increased to 320. To
calculate sample size, we used the equation:





 Age 40 to 79 years.
 Patients with IHF:◦ Left ventricular ejection fraction ≤45%, as
measured by echocardiography in modified
Simpson method.
◦ History of myocardial infarction with or without
percutaneous coronary intervention or coronary
artery bypass grafting.
◦ Coronary angiography or coronary computed
tomography angiography shows ≥50% stenosis in
at least one main coronary artery with or without
revascularization, which the researcher thinks is
closely related to HF.
◦ With or without dyspnea, fatigue and fluid
retention (edema), and so on.
 History of HF or present with HF symptoms for at
least 3 months.
 NYHA Class II to IV.
 Submitted informed consent.
Exclusion criteria
 Acute HF or acute exacerbation of chronic HF.
 Patients with one of the following diseases:◦ Acute coronary syndrome within 30 days.
◦ Revascularization therapy within 6 months.
◦ Uncontrolled hypertension with systolic pressure
≥180 mmHg or diastolic pressure ≥110 mmHg.
◦ Second-degree type 2 or worse sinoatrial or
atrioventricular block without implantation of
pacemaker or uncontrolled malignant cardiac
arrhythmia.
◦ Dilated cardiomyopathy.
◦ Hypertrophic obstructive cardiomyopathy.
◦ Myocarditis.
◦ Pulmonary artery embolism.
◦ Severe valvular heart disease
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◦ Stroke within 6 months.
 Cardiac resynchronization therapy.
 Applied diuretics, cardiotonic agents, or vasodilators
intravenously within 7 days.
 Severe endocrine diseases, such as hyperthyroidism.
 History of malignant tumor.
 Hemoglobin ≤ 9 g/dl.
 Alanine aminotransferase more than twice the upper
limit of normal.
 Serum creatinine >265 μmol/l.
 Mental disorder.
 Pregnant, planning for pregnancy or breastfeeding.
 Suspicious or definite allergy to intervention drugs.
 Participated in other trials within 2 months.
 Unable to walk autonomously, owing to physical
disabilities.
Randomization procedure
Included patients will be randomly assigned to a treat-
ment or control group in the ratio of 1:1. Stratification
will be performed on NYHA classification, enrolling
hospitals, and revascularization methods. Eligible pa-
tients will be randomized by IWRS/IVRS software
(ClinicalSoft Co. Ltd.) into the intervention arms. The
identification number and randomization code generated
are unique to each patient and correspond to the coded
boxes of either QSYQ or a placebo matched in appear-
ance, color, and shape to the drug. The flavor of the drug
and placebo are also similar. Blinding will be maintained
amongst the investigators and patients.
Interventions and study plan
Written informed consent will be obtained from all eli-
gible patients before enrolment. Subsequently, all enrolled
patients are screened for 10 ± 3 days (V0). During this
period, their Western medication will be standardized
according to their clinical conditions with reference to the
2010 HFSA comprehensive heart failure practice guideline
[5] and 2007 CSC guidelines for the treatment and diagno-
sis of chronic heart failure [6]. The standardized Western
medications include diuretics, angiotensin-converting en-
zyme inhibitor or angiotensin-receptor blocker, β-blockers
, aldosterone receptor antagonist, digoxin, and vasodilating
agents. To achieve a heart-healthy lifestyle, patients will
also be advised to restrict salt and water intake, monitor
weight, and maintain regular physical activities.
After screening, stable patients will be randomized to ei-
ther a treatment or control group at the baseline visit
(V1). Besides their standardized Western medicine, pa-
tients assigned to the treatment or control group will take
QSYQ or placebo, respectively. Patients have to take one
packet (0.52 g) of the study medication thrice daily, with
the first dose taken as soon as practically possible.Independent drug administrators will be responsible for
the delivery and dispensation of the study medications.
This trial has two phases: treatment and follow-up. In
the 6-months course of treatment, study medications will
be given to the patients, who are to attend study visits at
1, 3, and 6 months (V2, V3, and V4). After the treatment
phase, patients will enter a follow-up phase lasting for at
least another 6 months. During this follow-up period, pa-
tients are to attend study visits at 9 and 12 months (V5
and V6), and two additional study visits during extended
follow-up (V7, V8). The extended follow-up ends when
the last patient enrolled into the trial completes 12
months of treatment and follow-up. All the visits and con-
tents are described in Figure 1.
During the entire trial period, any other kinds of TCM
drugs are forbidden except for QSYQ or the placebo.
The study medication should be taken routinely for 6
months unless disallowed because of certain clinical
conditions. In the case of comorbidities (such as hyper-
tension or diabetes) and complications, appropriate
Western medicine can be given with reference to the
relevant guidelines. All drugs used should be recorded
up to date by the investigators. Patients should not hesi-
tate to seek emergency care if necessary.
Outcomes
Primary outcome
The 6MWT will be used to assess the exercise capacity of
the patients in this trial [22]. This test will be used for each
patient at study visits V1, V3, and V4, and conducted in
hospitals on a 30-meter track. The patients will be
instructed to walk as far as possible for 6 minutes, at a
self-determined speed and pausing to rest as needed. Be-
fore each test, the patient’s blood pressure, heart rate, and
oxygen saturation will be measured. Subsequently, effort
perception on the Borg scale will also be assessed. At the
end of each test, the same parameters will be measured
again. The result of the 6MWT is the total distance cov-
ered (in meters) in 6 minutes.
Secondary outcomes
Composite endpoints, including all-cause mortality, fre-
quency of hospitalization or emergency due to cardiovas-
cular events (exacerbated HF, acute coronary syndrome,
malignant ventricular arrhythmias, cardiac shock, revascu-
larization, stroke, pulmonary embolism, peripheral vascu-
lar events, and so on) will be documented at study visits
from V2 to V8. Additional secondary outcome measures,
such as brain natriuretic peptide levels, echocardiography
(including left ventricular ejection fraction quantified by
the Simpson method) and cardiothoracic ratio by radiog-
raphy will be included for the patients at study visits V1
and V4. The NYHA classification and Minnesota quality
of life scores, as well as information from the four TCM
Figure 1 Study visits.
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from V1 to V6.
Other measurements
Blood lipid tests (blood cholesterol, triglycerides, high-
density lipoprotein, and low-density lipoprotein) will be
carried out at study visits V1, V3, and V4.Safety
Safety will be assessed by vital signs, laboratory tests, ECG,
and adverse events. Vital signs, including heart rate and
blood pressure, will be monitored at enrolment and study
visits V1 to V6. Laboratory tests, such as routine blood
and urine tests, hepatic and renal function, and blood elec-
trolyte levels will be examined at study visits V1, V3, and
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V3, V4, V5, and V6. Adverse events will be documented at
every study visit and severe adverse events will be reported
to the principal investigator within 24 hours. In the case of
a medical necessity, the patients will be unblinded
according to the unblinding procedures on receiving per-
mission from the principal investigator. A negative preg-
nancy test is also mandatory before enrolment of women
of reproductive age.
A schedule of all evaluations is outlined in Figure 2.
Data collection
Patients will be followed up by a study investigator until the
end of trial, and all general data and outcome evaluations6MWT, composite endpoint, BNP, 
echocardiography (e.g. LVEF), cardiothoracic 
ratio, NYHA classification, Quality of life, TCM 
four diagnostic information, blood lipids
Central rand















Figure 2 Schedule of evaluations.will be recorded in the case report form at each study visit.
Investigators will also update an electronic database using
Oracle Clinical Remote Data Capture. This will provide
real-time monitoring of the database, to ensure the high
quality of data. At the end of the trial, the investigators, data
managers, and statisticians will perform blind review and
confirm the database before processing data.
Ethical aspects
This trial protocol was approved by the Ethics Commit-
tee of First Teaching Hospital of Tianjin University of
TCM on 2 December 2011 (TYLL2011 [K] 005). The
protocol and its informed consent form have been
judged ethically and scientifically satisfactory for the trialPhysical examination, 
laboratory test, adverse 
events
omization
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all participants or their legally authorized representatives
before enrollment. The trial has been registered with
both the Chinese Clinical Trial Registry of International
Clinical Trials Registry Platform of World Health
Organization and ClinicalTrial.gov of the U.S. National
Institutes of Health.
Statistical analysis
Statistical analysis for the trial will be performed by the
Centre for Statistical Science, Peking University. Statistics
software SAS 9.1 will be used for the data analysis.
Intention-to-treat analysis, per-protocol analysis, and
safety analysis will be conducted. Calculations for the out-
comes will be based on a two-tailed test, except for the
primary outcome, which will be a one-tailed test (level of
significance α = 0.05). Besides the statistical comparison
between baseline variables, the change in 6MWT result
between baseline and the assessment 3 and 6 months dur-
ing the treatment phase will be performed using analysis
of covariance adjusted for baseline and treatment to im-
prove the efficiency and power of the tests. Survival ana-
lysis will be conducted using Kaplan-Meier and Cox
regression models. Statistical analysis on the missing data
of the outcome measures will be adjusted using an esti-
mating equation or statistical model in the final analysis.
Sensitivity analyses will also be performed to assess the ro-
bustness of the data.
Discussion
The use of TCM alongside Western medicine in the
treatment of HF is a common practice in China and
has developed into an integrative treatment model. The
efficacy of the model to improve the exercise capacity,
quality of life, and symptoms of these patients has
been demonstrated in some small-scale clinical studies
[23-26]. However, there is a lack of high-quality evi-
dence to support the recommendation of integrative
treatment for HF.
QSYQ, as a TCM drug often used in IHF treatment,
has been studied in many small-scale clinical trials and
intensive experimental researches [9-19]. However, there
is still a demand for a high-quality and larger-scale clin-
ical research to prove its efficacy in the treatment of
IHF. As TCM is composed of multi-active components
and possesses multitarget action feature, it can provide a
holistic regulation of whole body and improve overall
condition of patients. To assess the results of the treat-
ment effectively, an appropriate outcome measure is re-
quired. QSYQ has showed its advantage in increasing
exercise capacity of IHF patients, therefore the 6MWT,
which has been proven to be a good measurement of ex-
ercise capacity [27,28], could be a proper primary out-
come test for the trial.The study protocol was designed with reference to
international clinical trial principles. Strict quality con-
trol measures were implemented and data were moni-
tored regularly. Quality control supervisors will ensure
that investigators adhere to the study protocol in each
investigation center. The trial has also applied IWRS and
Oracle Clinical Remote Data Capture to enhance data
management and reduce bias in the research. The rigor-
ous design of the trial will ensure an objective and scien-
tific assessment of the efficacy and safety of QSYQ in
the treatment of IHF.
Trial status
The CACT-IHF study has been recruiting patients
since March 2012. Study completion date is estimated
at August 2014. Clinical trials.gov number: NCT 01555320.
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